Regeneron Antibody Cocktail May Reduce COVID-19 Hospitalization by 70%

• Results from a phase 3 clinical trial show that Regeneron’s antibody cocktail has the ability to cut the risk of COVID-19 hospitalization and death by 70 percent.
• The treatment also shortened the duration of COVID-19 symptoms by 4 days.
• The two antibodies work similarly to the antibodies the immune system naturally produces to fight the coronavirus.

Regeneron’s monoclonal antibody drug treatment can reduce COVID-19 hospitalization and death by 70 percent, according to a press release published March 23.

The treatment also reduced the length of COVID-19 symptoms by 4 days, on average.

All Regeneron doses that were tested — 8,000 milligrams (mg), 2,400 mg, and 1,200 mg — were similarly effective.

Regeneron originally planned to have 750,000 doses available by June. If the lower doses are approved for use, the company could potentially produce 1.25 million by then.

The treatment was given to former President Donald Trump shortly after he contracted the coronavirus in October 2020. Trump’s condition improved soon after receiving the treatment.

The Regeneron antibody treatment, which was granted emergency use authorization for high-risk groups in November 2020, is the third antibody combination now available in the United States.